Experimental drug NU-9 reduces toxic amyloid in early Alzheimer’s
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
List view / Grid view
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
A new study is challenging long-held beliefs about dopamine’s role in movement, revealing new insights into how Parkinson’s disease treatments work and pointing towards more targeted future therapies.
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness.
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
Scientists have discovered that psilocin – the compound produced in the body from the psychedelic found in magic mushrooms – may reduce alcohol consumption by calming activity in brain regions linked to stress.
Scientists have discovered that two existing pain medications – bupivacaine and rimegepant – may not only relieve the severe pain caused by osteosarcoma but also slow the disease’s growth.
For the first time, researchers have demonstrated that flipping an epigenetic ‘switch’ in memory cells can directly control whether a memory is expressed or silenced, offering new insights into how memories are stored and potentially altered.
A circular RNA called circHomer1 has been found to play a vital role in forming and adjusting synapses in developing mouse brains, revealing an overlooked mechanism that helps visual neurons respond to changes in sensory input.
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.
Scientists have discovered a rare type of brain cell that appears to drive the chronic inflammation seen in progressive multiple sclerosis – which could potentially lead to new disease-modifying therapies.
Scientists have discovered that neurons can burn and make their own fats for energy – a finding that could lead to new treatments for rare and currently untreatable brain diseases.
Korean researchers have discovered that oral bacteria in the gut may contribute to Parkinson’s disease – highlighting a potential new target for treatment.
New research from Gladstone Institutes shows that chronic overactivation of dopamine-producing neurons can directly trigger their death, offering new insights into why these cells deteriorate in Parkinson’s disease which could lead to potential therapies to slow its progression.
Researchers at UC San Diego have discovered a graphene-based technology that accelerates the maturation of human brain organoids, offering a safer, non-invasive way to model diseases like Alzheimer’s.
Porosome Therapeutics has announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.